What is the role of GM-1 in the treatment of spinal cord injury (SCI)?

Updated: Nov 01, 2018
  • Author: Lawrence S Chin, MD, FACS, FAANS; Chief Editor: Brian H Kopell, MD  more...
  • Print

Two North American studies have addressed the administration of monosialotetrahexosyl ganglioside (GM-1) following acute spinal cord injury. The available medical evidence does not support a significant clinical benefit. It was evaluated as a treatment adjunct after the administration of methylprednisolone. [5, 52]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!